Related references
Note: Only part of the references are listed.Secukinumab in Plaque Psoriasis - Results of Two Phase 3 Trials
Richard G. Langley et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study
K. A. Papp et al.
BRITISH JOURNAL OF DERMATOLOGY (2013)
Improving adherence to injectable disease-modifying drugs in multiple sclerosis
Antonios Bayas
EXPERT OPINION ON DRUG DELIVERY (2013)
The Emerging Role of IL-17 in the Pathogenesis of Psoriasis: Preclinical and Clinical Findings
David A. Martin et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2013)
Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomised, double-blind, placebo-controlled, phase II regimen-finding study
P. Rich et al.
BRITISH JOURNAL OF DERMATOLOGY (2012)
The potential of interleukin-17 to mediate hematopoietic response
Aleksandra Krstic et al.
IMMUNOLOGIC RESEARCH (2012)
Patient satisfaction with injection devices: a randomized controlled study comparing two different etanercept delivery systems in moderate to severe psoriasis
C. Paul et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2012)
Adherence in the Treatment of Psoriasis: A Systematic Review
M. Augustin et al.
DERMATOLOGY (2011)
Assessment of self-injection experience in patients with rheumatoid arthritis: psychometric validation of the Self-Injection Assessment Questionnaire (SIAQ)
Dorothy Keininger et al.
HEALTH AND QUALITY OF LIFE OUTCOMES (2011)
IL-17 signaling in host defense against Candida albicans
Sarah L. Gaffen et al.
IMMUNOLOGIC RESEARCH (2011)
Maximizing patient adherence for optimal outcomes in psoriasis
A. Bewley et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2011)
Supportive strategies to improve adherence to IFN beta-1b in Multiple Sclerosis - Results of the BetaPlus observational cohort study
Carlo Pozzilli et al.
JOURNAL OF THE NEUROLOGICAL SCIENCES (2011)
Increased Th17 cells are accompanied by FoxP3(+) Treg cell accumulation and correlated with psoriasis disease severity
Li Zhang et al.
CLINICAL IMMUNOLOGY (2010)
Effects of AIN457, a Fully Human Antibody to Interleukin-17A, on Psoriasis, Rheumatoid Arthritis, and Uveitis
Wolfgang Hueber et al.
SCIENCE TRANSLATIONAL MEDICINE (2010)
Addressing the need for increased adherence to multiple sclerosis therapy: can delivery technology enhance patient motivation?
Alessandra Lugaresi
EXPERT OPINION ON DRUG DELIVERY (2009)
Interleukin-17 as a drug target in human disease
Stefan Ivanov et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2009)
Clinical assessment of pain, tolerability, and preference of an autoinjection pen versus a prefilled syringe for patient self-administration of the fully human, monoclonal antibody adalimumab: The TOUCH trial
Alan Kivitz et al.
CLINICAL THERAPEUTICS (2006)
Better medication adherence results in greater improvement in severity of psoriasis
CL Carroll et al.
BRITISH JOURNAL OF DERMATOLOGY (2004)
Immunopathogenic mechanisms in psoriasis
JE Gudjonsson et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2004)
Share Paper
